GLI4: A Non-Coding RNA Molecule as A Potential Drug Target and Biomarker

Target Name: GLI4

NCBI ID: G2738

GLI4

GLI4: A Non-Coding RNA Molecule as A Potential Drug Target and Biomarker

GLI4 (GLI-Kruppel family member GLI4) is a non-coding RNA molecule that has been identified as a potential drug target or biomarker for various diseases, including cancer. GLI4 is a member of the GLI family, which is known for its role in regulating gene expression and cell proliferation. GLI4 has been shown to play a role in the regulation of cell cycle progression, and its expression has been associated with the development and progression of various diseases.

One of the key features of GLI4 is its ability to interact with other molecules, including the oncogene HKR4. HKR4 is a viral oncogene that has been shown to promote the growth and survival of various cancer cells. GLI4 has been shown to interact with HKR4 and to play a role in the regulation of its activity. This interaction between GLI4 and HKR4 makes GLI4 an attractive target for drug development, as it may be possible to use GLI4 as a means of inhibiting the activity of HKR4 and treating cancer.

In addition to its potential as a drug target, GLI4 has also been shown to be a potential biomarker for various diseases. The GLI4 gene has been shown to be expressed in a variety of tissues and cells, including cancer cells, and its expression has been associated with the development and progression of various diseases. For example, GLI4 has been shown to be overexpressed in various types of cancer, including breast cancer, lung cancer, and colon cancer. This finding suggests that GLI4 may be a useful biomarker for the diagnosis and treatment of these diseases.

Another potential aspect of GLI4 is its role in the regulation of cell signaling pathways. GLI4 has been shown to play a role in the regulation of the PI3K/Akt signaling pathway, a pathway that is involved in various cellular processes, including cell survival and proliferation. This suggests that GLI4 may be involved in the regulation of cellular processes that are important for the survival and growth of cancer cells.

GLI4 has also been shown to play a role in the regulation of cellular processes that are important for the development and progression of other diseases. For example, GLI4 has been shown to be involved in the regulation of cell adhesion, a process that is important for the development and maintenance of tissues and organs. This suggests that GLI4 may be involved in the regulation of cellular processes that are important for the development and progression of diseases such as heart disease and neurodegenerative diseases.

In conclusion, GLI4 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases. Its ability to interact with the oncogene HKR4 and its involvement in the regulation of cell cycle progression, signaling pathways, and cellular processes important for the development and progression of diseases make GLI4 an attractive target for drug development and biomarker research. Further studies are needed to fully understand the role of GLI4 in the regulation of cellular processes and its potential as a drug target and biomarker.

Protein Name: GLI Family Zinc Finger 4

The "GLI4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GLI4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets